2019
Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker
Swanberg KM, Landheer K, Pitt D, Juchem C. Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker. Frontiers In Neurology 2019, 10: 1173. PMID: 31803127, PMCID: PMC6876616, DOI: 10.3389/fneur.2019.01173.Peer-Reviewed Original ResearchMultiple sclerosisProton magnetic resonance spectroscopyDiagnostic biomarkersH-MRSStudy designVivo proton magnetic resonance spectroscopyCentral nervous system tissueNormal-appearing white matterNumerous metabolic alterationsPotential diagnostic biomarkersNervous system tissueMetabolic abnormalitiesH-MRS dataSpinal cordLesion compositionSclerosisMetabolic alterationsWhite matterGray matterMagnetic resonance spectroscopyMetabolic signaturesBiomarkersExperimental cohortLines of evidenceTechnical considerations
2000
Insulin-Like Growth Factor-1 Fails to Enhance Central Nervous System Myelin Repair during Autoimmune Demyelination
Cannella B, Pitt D, Capello E, Raine C. Insulin-Like Growth Factor-1 Fails to Enhance Central Nervous System Myelin Repair during Autoimmune Demyelination. American Journal Of Pathology 2000, 157: 933-943. PMID: 10980132, PMCID: PMC1885703, DOI: 10.1016/s0002-9440(10)64606-8.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor-1Experimental autoimmune encephalomyelitisCentral nervous system tissueGrowth factor-1Nervous system tissueAcute phaseChronic phaseChronic time pointsTime pointsVehicle-treated groupIGF-1 administrationVehicle-treated controlsFactor 1Oligodendrocyte progenitor populationClinical ameliorationAutoimmune encephalomyelitisCytokine levelsDifferent time pointsTreatment regimenAutoimmune demyelinationMultiple sclerosisSJL miceMyelin regenerationMyelin repairTGF-beta2